The combination of MSU42011 plus anti-PD1 (130.7% vs. 62.5%, % of control, p < 0.0001) or anti-PDL1 (111.1% vs. 71.5%, % of control, p = 0.017) was more effective for reducing tumor size than antibodies alone (Table 2, Figure 7B) or the isotype control group. This evidence concerns the gene CD274 and neoplasm.